Q2-osavuosiraportti
84 päivää sitten‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
1 200
Myynti
Määrä
15 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 5.6. | |
| 2024 Q4-osavuosiraportti | 10.4. | |
| 2024 Q2-osavuosiraportti | 29.8.2024 | |
| Merkintäoikeusanti | 20.6.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·4 t sittenIn short, according to the stock exchange announcements, Atlas sold approximately 4 million shares on November 18, which corresponds to the maximum limit of 15% sales per day at high volume. It is assumed that they sold approximately the same the day after. With approximately 15.6 million shares remaining, they will, if they continue at the same pace (approx. 4 million per day), be able to complete the sales within approximately four days. This coincides timely with Monday's webcast, where an updated status is expected. It is speculated that this could contribute to higher bottoms going forward. You can read the newsweb messages and make your own interpretation. ⏳⏳🎁🎄
·9 min sittenTechnically strong as a bear https://www.tradingview.com/symbols/OSL-CRNA/technicals/
·7 t sittenAs the last registered trading day is always one day delayed, tomorrow will show that Atlas sold down from 23.53 M to 19.62M Reduced ownership stake from 16.38% to 13.36% They made a good profit on shares they bought for 0.6 and sold for 1.5-ish on average, and pulled the price down from 1.6 to 1.4. The price will rise again due to the positive developments in the company. Atlas will sell several large blocks which will temporarily pull the price down. But it will rise again time and again. Eventually, Atlas will have emptied its holdings, and we will rocket up. So hold!! Don't sell in panic when Atlas sells and the price takes a step down. And if you have cash on hand, take the chance to add more when Atlas sells and the price gets a dip. We will go up, up, up!!- ·7 t sitten · MuokattuTrades among the 50 largest shareholders last registered trading day 18 to 19 nov Buy Nordnet livsforsikring up 161K Ole Andre Skotheim up 0.5K Håvard Hagavei up 50K Sell Citibank N.A. (Atlas) down 35K Nordnet bank down 2K Remaining 45vav 50 sit still I the boat.
- ·11 t sittenfar too little has been written about this news.. That the feasibility study is fully financed by a world-leading (global top-tier) pharmaceutical company means far more than what is explicitly stated in the announcement. In the biotech world, this is a strong signal — and the market often underestimates what this truly entails. Here's what it usually means in practice: 1) The large company takes all the risk in this phase When a global pharma player pays 100 % of a feasibility study: They invest time, money, and resources already now. They only do this if the technology is relevant for their pipeline and fills a gap they cannot solve themselves. They prioritize internal time and laboratory capacity → this is expensive for them. If they didn't believe the technology had potential, they would never have financed the phase themselves. 2) It means the technology is considered “strategically interesting” Big pharma NEVER pays for something that is only “a little interesting”. This normally means that: the technology can solve an important problem (e.g. dose, toxicity, effect) they see commercial value there is an internal champion / scientific sponsor pushing this forward This is a much stronger signal than a simple “collaboration”, where costs are shared. 3) They want a first look or a position The large company wants to be first in line They gain insight into the technology and datasets before competitors. This is very valuable to them. 4) They see technology that can solve one of the AAV industry's biggest problems AAV technology struggles with: low gene expression need for high doses (causes toxicity) limits which diseases can be reached If Circio actually shows 10–40× improved expression, it is one of the most valuable technology leaps within AAV in the last 10 years. Therefore, a top-tier pharmaceutical company wants to test this early. 5) It dramatically increases the likelihood of a license or partnership agreement Although nothing is guaranteed, statistics show that: When big pharma finances a feasibility study, and the technology delivers beyond expectation, → 50–70 % of such studies are followed by some form of agreement (collaboration, license, or exclusive option). This is a high conversion rate in biotech. 6) It is also a quality signal to other potential partners When one top-tier company puts money on the table: increases the likelihood that other pharmaceutical companies show interest it dramatically strengthens the negotiating position it can lead to better terms in future agreements it makes capital raising easier (better conditions, less dilution) This is often more important than the money in the study itself. 7) It strengthens Circio's negotiating power in financing The company wants a different financing solution than Atlas, and: a validation from global pharma PLUS that the partner pays themselves PLUS that the study is aimed at a specific therapeutic area → makes Circio much more attractive to investors and strategic funds. This might be exactly what is needed for Circio to refinance without Atlas. Briefly explained — in one line When a global pharma giant pays for the feasibility study, it means that Circio's technology is considered a real potential breakthrough, not just interesting theory.·9 t sittenIf it were that simple, everyone would have mortgaged their house to the hilt and put 10 million here and had a debt-free house next week!, but that's probably not the case!, suffered a setback on so many of these stocks before, just sold them off at a huge loss, but always recovered in others
- ·11 t sitten · MuokattuWe should of course not say 100 percent certain that AI has everything right, but it is very interesting to feed in all the info we have and let it gather and compare with other companies. One main point is the following… Financing without Atlas ( share issue, grant, upfront partner) - Removes a large part of negative sentiment - The stock potentially has a 3-4 x rerating just on an improved financing structure. As of now with a mcap of approx 200 million, Circio is at the low end of what one normally sees for companies with potentially groundbreaking gene therapy technology.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
84 päivää sitten‧37 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenIn short, according to the stock exchange announcements, Atlas sold approximately 4 million shares on November 18, which corresponds to the maximum limit of 15% sales per day at high volume. It is assumed that they sold approximately the same the day after. With approximately 15.6 million shares remaining, they will, if they continue at the same pace (approx. 4 million per day), be able to complete the sales within approximately four days. This coincides timely with Monday's webcast, where an updated status is expected. It is speculated that this could contribute to higher bottoms going forward. You can read the newsweb messages and make your own interpretation. ⏳⏳🎁🎄·9 min sittenTechnically strong as a bear https://www.tradingview.com/symbols/OSL-CRNA/technicals/
- ·7 t sittenAs the last registered trading day is always one day delayed, tomorrow will show that Atlas sold down from 23.53 M to 19.62M Reduced ownership stake from 16.38% to 13.36% They made a good profit on shares they bought for 0.6 and sold for 1.5-ish on average, and pulled the price down from 1.6 to 1.4. The price will rise again due to the positive developments in the company. Atlas will sell several large blocks which will temporarily pull the price down. But it will rise again time and again. Eventually, Atlas will have emptied its holdings, and we will rocket up. So hold!! Don't sell in panic when Atlas sells and the price takes a step down. And if you have cash on hand, take the chance to add more when Atlas sells and the price gets a dip. We will go up, up, up!!
- ·7 t sitten · MuokattuTrades among the 50 largest shareholders last registered trading day 18 to 19 nov Buy Nordnet livsforsikring up 161K Ole Andre Skotheim up 0.5K Håvard Hagavei up 50K Sell Citibank N.A. (Atlas) down 35K Nordnet bank down 2K Remaining 45vav 50 sit still I the boat.
- ·11 t sittenfar too little has been written about this news.. That the feasibility study is fully financed by a world-leading (global top-tier) pharmaceutical company means far more than what is explicitly stated in the announcement. In the biotech world, this is a strong signal — and the market often underestimates what this truly entails. Here's what it usually means in practice: 1) The large company takes all the risk in this phase When a global pharma player pays 100 % of a feasibility study: They invest time, money, and resources already now. They only do this if the technology is relevant for their pipeline and fills a gap they cannot solve themselves. They prioritize internal time and laboratory capacity → this is expensive for them. If they didn't believe the technology had potential, they would never have financed the phase themselves. 2) It means the technology is considered “strategically interesting” Big pharma NEVER pays for something that is only “a little interesting”. This normally means that: the technology can solve an important problem (e.g. dose, toxicity, effect) they see commercial value there is an internal champion / scientific sponsor pushing this forward This is a much stronger signal than a simple “collaboration”, where costs are shared. 3) They want a first look or a position The large company wants to be first in line They gain insight into the technology and datasets before competitors. This is very valuable to them. 4) They see technology that can solve one of the AAV industry's biggest problems AAV technology struggles with: low gene expression need for high doses (causes toxicity) limits which diseases can be reached If Circio actually shows 10–40× improved expression, it is one of the most valuable technology leaps within AAV in the last 10 years. Therefore, a top-tier pharmaceutical company wants to test this early. 5) It dramatically increases the likelihood of a license or partnership agreement Although nothing is guaranteed, statistics show that: When big pharma finances a feasibility study, and the technology delivers beyond expectation, → 50–70 % of such studies are followed by some form of agreement (collaboration, license, or exclusive option). This is a high conversion rate in biotech. 6) It is also a quality signal to other potential partners When one top-tier company puts money on the table: increases the likelihood that other pharmaceutical companies show interest it dramatically strengthens the negotiating position it can lead to better terms in future agreements it makes capital raising easier (better conditions, less dilution) This is often more important than the money in the study itself. 7) It strengthens Circio's negotiating power in financing The company wants a different financing solution than Atlas, and: a validation from global pharma PLUS that the partner pays themselves PLUS that the study is aimed at a specific therapeutic area → makes Circio much more attractive to investors and strategic funds. This might be exactly what is needed for Circio to refinance without Atlas. Briefly explained — in one line When a global pharma giant pays for the feasibility study, it means that Circio's technology is considered a real potential breakthrough, not just interesting theory.·9 t sittenIf it were that simple, everyone would have mortgaged their house to the hilt and put 10 million here and had a debt-free house next week!, but that's probably not the case!, suffered a setback on so many of these stocks before, just sold them off at a huge loss, but always recovered in others
- ·11 t sitten · MuokattuWe should of course not say 100 percent certain that AI has everything right, but it is very interesting to feed in all the info we have and let it gather and compare with other companies. One main point is the following… Financing without Atlas ( share issue, grant, upfront partner) - Removes a large part of negative sentiment - The stock potentially has a 3-4 x rerating just on an improved financing structure. As of now with a mcap of approx 200 million, Circio is at the low end of what one normally sees for companies with potentially groundbreaking gene therapy technology.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
1 200
Myynti
Määrä
15 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 5.6. | |
| 2024 Q4-osavuosiraportti | 10.4. | |
| 2024 Q2-osavuosiraportti | 29.8.2024 | |
| Merkintäoikeusanti | 20.6.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
84 päivää sitten‧37 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 5.6. | |
| 2024 Q4-osavuosiraportti | 10.4. | |
| 2024 Q2-osavuosiraportti | 29.8.2024 | |
| Merkintäoikeusanti | 20.6.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenIn short, according to the stock exchange announcements, Atlas sold approximately 4 million shares on November 18, which corresponds to the maximum limit of 15% sales per day at high volume. It is assumed that they sold approximately the same the day after. With approximately 15.6 million shares remaining, they will, if they continue at the same pace (approx. 4 million per day), be able to complete the sales within approximately four days. This coincides timely with Monday's webcast, where an updated status is expected. It is speculated that this could contribute to higher bottoms going forward. You can read the newsweb messages and make your own interpretation. ⏳⏳🎁🎄·9 min sittenTechnically strong as a bear https://www.tradingview.com/symbols/OSL-CRNA/technicals/
- ·7 t sittenAs the last registered trading day is always one day delayed, tomorrow will show that Atlas sold down from 23.53 M to 19.62M Reduced ownership stake from 16.38% to 13.36% They made a good profit on shares they bought for 0.6 and sold for 1.5-ish on average, and pulled the price down from 1.6 to 1.4. The price will rise again due to the positive developments in the company. Atlas will sell several large blocks which will temporarily pull the price down. But it will rise again time and again. Eventually, Atlas will have emptied its holdings, and we will rocket up. So hold!! Don't sell in panic when Atlas sells and the price takes a step down. And if you have cash on hand, take the chance to add more when Atlas sells and the price gets a dip. We will go up, up, up!!
- ·7 t sitten · MuokattuTrades among the 50 largest shareholders last registered trading day 18 to 19 nov Buy Nordnet livsforsikring up 161K Ole Andre Skotheim up 0.5K Håvard Hagavei up 50K Sell Citibank N.A. (Atlas) down 35K Nordnet bank down 2K Remaining 45vav 50 sit still I the boat.
- ·11 t sittenfar too little has been written about this news.. That the feasibility study is fully financed by a world-leading (global top-tier) pharmaceutical company means far more than what is explicitly stated in the announcement. In the biotech world, this is a strong signal — and the market often underestimates what this truly entails. Here's what it usually means in practice: 1) The large company takes all the risk in this phase When a global pharma player pays 100 % of a feasibility study: They invest time, money, and resources already now. They only do this if the technology is relevant for their pipeline and fills a gap they cannot solve themselves. They prioritize internal time and laboratory capacity → this is expensive for them. If they didn't believe the technology had potential, they would never have financed the phase themselves. 2) It means the technology is considered “strategically interesting” Big pharma NEVER pays for something that is only “a little interesting”. This normally means that: the technology can solve an important problem (e.g. dose, toxicity, effect) they see commercial value there is an internal champion / scientific sponsor pushing this forward This is a much stronger signal than a simple “collaboration”, where costs are shared. 3) They want a first look or a position The large company wants to be first in line They gain insight into the technology and datasets before competitors. This is very valuable to them. 4) They see technology that can solve one of the AAV industry's biggest problems AAV technology struggles with: low gene expression need for high doses (causes toxicity) limits which diseases can be reached If Circio actually shows 10–40× improved expression, it is one of the most valuable technology leaps within AAV in the last 10 years. Therefore, a top-tier pharmaceutical company wants to test this early. 5) It dramatically increases the likelihood of a license or partnership agreement Although nothing is guaranteed, statistics show that: When big pharma finances a feasibility study, and the technology delivers beyond expectation, → 50–70 % of such studies are followed by some form of agreement (collaboration, license, or exclusive option). This is a high conversion rate in biotech. 6) It is also a quality signal to other potential partners When one top-tier company puts money on the table: increases the likelihood that other pharmaceutical companies show interest it dramatically strengthens the negotiating position it can lead to better terms in future agreements it makes capital raising easier (better conditions, less dilution) This is often more important than the money in the study itself. 7) It strengthens Circio's negotiating power in financing The company wants a different financing solution than Atlas, and: a validation from global pharma PLUS that the partner pays themselves PLUS that the study is aimed at a specific therapeutic area → makes Circio much more attractive to investors and strategic funds. This might be exactly what is needed for Circio to refinance without Atlas. Briefly explained — in one line When a global pharma giant pays for the feasibility study, it means that Circio's technology is considered a real potential breakthrough, not just interesting theory.·9 t sittenIf it were that simple, everyone would have mortgaged their house to the hilt and put 10 million here and had a debt-free house next week!, but that's probably not the case!, suffered a setback on so many of these stocks before, just sold them off at a huge loss, but always recovered in others
- ·11 t sitten · MuokattuWe should of course not say 100 percent certain that AI has everything right, but it is very interesting to feed in all the info we have and let it gather and compare with other companies. One main point is the following… Financing without Atlas ( share issue, grant, upfront partner) - Removes a large part of negative sentiment - The stock potentially has a 3-4 x rerating just on an improved financing structure. As of now with a mcap of approx 200 million, Circio is at the low end of what one normally sees for companies with potentially groundbreaking gene therapy technology.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
1 200
Myynti
Määrä
15 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt